Drug Profile
Amifampridine - BioMarin
Alternative Names: 3,4-DAP; 3,4-DAP phosphate; 3,4-DAPP; 3,4-Diaminopyridine; 3,4-Pyridinediamine-phosphate; Amifampridine phosphate; DAPP; Firdapse; Pyridine-3,4-diamine-monophosphate; ZenasLatest Information Update: 21 Dec 2023
Price :
$50
*
At a glance
- Originator Assistance Publique Hopitaux de Paris
- Developer BioMarin Pharmaceutical; Catalyst Pharmaceuticals; DyDo Pharma; Fondazione Istituto Neurologico Carlo Besta
- Class Aminopyridines; Antineoplastics; Small molecules
- Mechanism of Action Acetylcholine stimulants; Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Lambert-Eaton myasthenic syndrome
- Phase III Congenital myasthenic syndromes; Myasthenia gravis
- Discontinued Spinal muscular atrophy